As part of the country's grandiose "Golden Dome" air defense project, the US Space Force has begun awarding prototype contracts for space-based interceptors, SpaceNews reports. These designs will ...

The US Space Force awarded multiple small contracts to develop prototypes for space-based interceptors, looking for progress with a technology that has yet to be proven but forms a crucial part of ...

The United States faces a challenge to maintain adequate stockpiles of missile interceptors amid rising demand and limited production capacity. The strain spans multiple systems. For example, concerns ...

While on a 7,500-mile trip around the Pacific Ocean this past summer, a small surface drone caught an unexpected sight: a Chinese navy destroyer. That small vessel was Lightfish, an autonomous surface ...

The US Army has awarded a contract for prototyping a second interceptor for the Indirect Fire Protection Capability to Lockheed Martin. (Lockheed Martin) Lockheed Martin has won an other transaction ...

The U.S. Army may revive the program to field a Patriot interceptor replacement. Credit: U.S. Department of Defense A year after the U.S. Army appeared to turn its back on a program to develop a ...

Today, we are excited to announce Varonis Interceptor, AI-native email security. AI has enabled a new breed of email threats that are more deceptive than ever. By mimicking tone, language, branding, ...

There were six violations of a restricted airspace over Bedminster, New Jersey, while President Donald Trump was staying at his residence there over the weekend, the U.S. Air Force said. One of those ...

While the path for any drug to go from lab research to commercialization takes years, Intercept Pharmaceuticals now stands as another example that a product’s market exit can also be long and winding.

Please provide your email address to receive an email when new articles are posted on . Intercept has voluntarily withdrawn its lone product, Ocaliva, from U.S. market for primary biliary cholangitis.

Sept 11 (Reuters) - Intercept Pharmaceuticals said on Thursday it is withdrawing its liver disease drug from the U.S. market following a request from the Food and Drug Administration. This comes as ...